137-45-1

Basic information

• Product Name: 3H-PYRAZOL-3-ONE, 1,2-DIHYDRO-
• Synonyms: 3H-PYRAZOL-3-ONE, 1,2-DIHYDRO-;1,2-dihydropyrazol-3-one;1,2-Dihydro-3H-pyrazol-3-one;1,2-dihydropyrazol-3-on;1H-Pyrazol-3-one;3-Hydroxypyrazole;Pyrazol-5-ol;Pyrazol-3-ol
• CAS NO: 137-45-1
• Molecular Formula: C3H4N2O
• Molecular Weight: 84.07666
• EINECS: 257-808-3
• Mol File: 137-45-1.mol
• Article Data: 33

Chemical Properties

• Melting Point: 160-162 °C
• Boiling Point: 326.1 °C at 760 mmHg
• Flash Point: 151 °C
• Appearance: /
• Density: 1.191 g/cm³
• Vapor Pressure: 0.000116mmHg at 25°C
• Refractive Index: 1.486
• Storage Temp.: 2-8°C
• PKA: 9.00±0.70(Predicted)
• CAS DataBase Reference: 3H-PYRAZOL-3-ONE, 1,2-DIHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-PYRAZOL-3-ONE, 1,2-DIHYDRO-(137-45-1)
• EPA Substance Registry System: 3H-PYRAZOL-3-ONE, 1,2-DIHYDRO-(137-45-1)

Safety Data

• Hazardous Substances Data: 137-45-1(Hazardous Substances Data)

Usage

General Description

"3H-Pyrazol-3-one, 1,2-dihydro-" is a chemical compound that belongs to the class of pyrazoles. It is a white to light yellow solid with a molecular formula of C3H4N2O and a molecular weight of 84.08 g/mol. This chemical is commonly used in the synthesis of pharmaceuticals and agrochemicals and is also used as a building block for various organic compounds. Its versatile nature and reactivity make it a valuable intermediate in the production of a wide range of products in the chemical industry. Additionally, it has potential applications in the field of medicinal chemistry and drug development.

InChI:InChI=1/C3H4N2O/c6-3-1-2-4-5-3/h1-2H,(H2,4,5,6)

Upstream product

• 58-96-8 uridine 
• 16205-84-8 ethyl 3-(trimethylsilyl)propynoate 
• 5329-12-4 (2,4,6-trichlorophenyl)hydrazine 
• 100-01-6 4-nitro-aniline 
• 56240-95-0 pyrazol-3-one 
• 7251-53-8 3-hydroxypyrazole-4-carboxylic acid ethyl ester 
• 34846-90-7 methyl 3-methoxyprop-2-enoate 
• 623-47-2 propynoic acid ethyl ester 
• 922-67-8 propynoic acid methyl ester 
• 69128-14-9 (2,6-dichloro-4-nitro-phenyl)-hydrazine 
• 554-00-7 2,4-Dichloroaniline 
• 1646-26-0 1-(benzo[b]furan-2-yl)ethanone 
• 105-58-8 Diethyl carbonate 
• 4498-67-3 1H-Indazole-3-carboxylic acid 

Downstream Products

• 76205-19-1 1-(para-chlorophenyl)-3-hydroxypyrazole 
• 2238821-33-3 tert-butyl (6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-6-yl)carbamate 
• 1706438-18-7 rac-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine 
• 852471-15-9 1-(3-hydroxy-1H-pyrazol-1-yl)ethan-1-one 
• 852471-15-9 1-acetyl-1,2-dihydro-3H-pyrazol-3-one 
• 288-13-1 NH-pyrazole 
• 342652-75-9 5-Hydroxymethyl-3-(1-methyl-1H-[1,2,4]triazol-3-ylmethoxy)-4-phenylpyrazole 
• 265643-78-5 4-tert-Butyl-5-hydroxymethyl-3-[(4-methylphenyl)sulphonyloxy]pyrazole 
• 3514-11-2 1,2-dimethyl-1,2-dihydropyrazol-3-on 
• 215610-30-3 3-methoxy-1H-pyrazole 

Relevant articles and documents

COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION

Heterocyclic compounds with a novel pyrazole thioamide-based NNSN structural motif, having highly effective zinc- or copper-activated toxicity against microbial infections at micromolar or nanomolar minimum inhibitory concentrations (MIC), and methods of making and using same.

Nickel-Catalyzed C-O Cross-Coupling Reaction at Low Catalytic Loading with Weak Base Participation

Herein, we report a nickel-catalyzed crossing-coupling reaction for the synthesis of diaryl ethers. The desired products are achieved by coupling heterocyclic alcohols with aryl bromides bearing strong electron withdrawing nitro group under the catalyst system of NiCl2(PPh3)2 and weak base KHCO3. This mild reaction exhibits a broad functional group tolerance. Compound 4 as an important intermediate is suitable for further structural modification of MALT1 inhibitor MI-2.

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies.